H.C. Wainwright analyst Yi Chen initiated coverage of VolitionRx (VNRX) with a Buy rating and $2.50 price target VolitionRx is a diagnostics company focused on the development of epigenetic tests based on nucleosomes that can enable early detection of diseases including certain cancers and sepsis, the analyst tells investors in a research note. The firm says the company’s Nu.Q diagnostic technology is validated by the commercialized Nu.Q Vet cancer test.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNRX: